The expressions of SREBP‐1c and its target lipogenic genes are increased in the livers of human NAFLD patients[7, 8] and animal models of NAFL.[9, 10] Knockdown or inhibition of SREBP‐1c or its target lipogenic enzymes, such as ACC, SCD1, ELOVL6, and GPAT, reduced hepatic lipid deposition in NAFLD animals and patients,[11, 12, 13] indicating the critical contribution of SREBP‐1c to hepatic steatosis. The gene discussed is GPAM; the disease is metabolic dysfunction-associated steatotic liver disease.